Page 79 - Aet News Today

The digital health sector's quarterly investment trends seem to be stabilizing in 2023, according to a new report from Rock Health. The report noted investors are shifting their focus away from pandemic-era categories like telehealth and pharmaceutical R&D catalysts — instead, they're interested in startups creating products for disease treatment, the improvement of nonclinical workflows and the enablement of value-based care.

Providence announced that it will spin out its fourth digital health startup in the first quarter of next year. The company, called Praia Health, offers a platform designed to build stronger relationships with patients by personalizing their healthcare journeys and connecting them to relevant resources and services.

Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.

ICHRAs provide employees with more choice on their health benefits. But many employers aren't very familiar with the new insurance model, executives say.

What does the future hold with AI and the healthcare ecosystem? Camille Harrison with GuideWell, Florida Blue joins the Payer's Place to share her thoughts.

Investment trends will be a big theme at the HLTH event at the Las Vegas Convention Center October 8-11. In the runup to the conference, investors from Bessemer Venture Partners, Cleveland Clinic Innovations, Third Culture Capital and Intuitive Ventures offered their takes on 2023 investments.

Diana Health, which partners with hospitals to operate a network of maternity practices, closed a $34 million Series B funding round. The startup currently operates three women's health practices in Tennessee. With its new funding, the company plans to open new practices in Tennessee, Florida and one other yet-to-be-announced state.

The Orchard Therapeutics acquisition comes as the biotech’s gene therapy for metachromatic leukodystrophy approaches a March 2024 FDA decision. The ex vivo gene therapy is already commercialized in Europe, marketed as Libmeldy.

Novavax’s updated version of its Covid-19 vaccine is now FDA authorized for use in the U.S., joining the approved shots from Moderna and partners Pfizer and BioNTech. Novavax said its protein-based vaccine will be available in coming days.

A new survey shows that women want more comprehensive medical support, solutions that treat their specific health concerns, access to a doctor who identifies the root cause of their symptoms and better care management services.